 |
|
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):150-163. Published online 2021 Nov 10 DOI: https://doi.org/10.3350/cmh.2021.0310
|
|
Citations to this article as recorded by
 The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro
Hepatology Research.2023; 53(2): 104. CrossRef Metabolic-associated fatty liver disease and the risk of cardiovascular disease
Pengwei Zhang, Xianhui Dong, Wei Zhang, Shiyin Wang, Chen Chen, Jiake Tang, Yao You, Siqi Hu, Shenghui Zhang, Chunyi Wang, Wen Wen, Mengyun Zhou, Tao Tan, Guanming Qi, Li Li, Mingwei Wang
Clinics and Research in Hepatology and Gastroenterology.2023; 47(1): 102063. CrossRef Utility of Indices Obtained During Medical Checkups for Predicting Fatty Liver Disease in Non-obese People
Naoya Otsubo, Tatsuya Fukuda, Cho Genhin, Fumiaki Ishibashi, Tetsuya Yamada, Koshiro Monzen
Internal Medicine.2023;[Epub] CrossRef Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
Liver International.2023; 43(3): 608. CrossRef New Concept of Fatty Liver: Metabolic dysfunction-associated fatty liver disease
Takumi Kawaguchi
Kanzo.2023; 64(2): 33. CrossRef The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases
Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Nutrients.2023; 15(5): 1123. CrossRef MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clinical and Molecular Hepatology.2023; 29(Suppl): S17. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors
Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Kenichi Nakamichi, Eiji Saegusa, Hidetoshi Ogura, Masaki Kato, Etsuko Doi, Naoko Inoue, Hitomi Sezaki, Tetsuya Hosaka, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Hiromi
Hepatology Research.2023;[Epub] CrossRef Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists?
Chi-Ho Lee
Primary Care Diabetes.2022;[Epub] CrossRef Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease
Tsubasa Tsutsumi, Takumi Kawaguchi, Dan Nakano, Takuji Torimura
Hepatology Research.2022; 52(3): 317. CrossRef Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 269. CrossRef MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups
Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn, Kwan Sik Lee, Byoung Kwon Lee, Su Jung Baik, Seung Up Kim, Jung Il Lee
Digestive Diseases and Sciences.2022; 67(10): 4919. CrossRef Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis
Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi, Mohammed Eslam, Shinobu Yoshinaga, Hirohiko Abe, Ryuichi Nouno, Seiya Joh, Keiichi Mitsuyama, Jacob George, Takuji Torimura
Hepatology Research.2022; 52(8): 699. CrossRef Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients
Susumu Inamine, Masayoshi Kage, Jun Akiba, Takumi Kawaguchi, Sachiyo Yoshio, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Ryuki Hashida, Kouichi Oshiro
Hepatology Research.2022; 52(10): 841. CrossRef MAFLD, patient-centred care, and APASL
Shiv K. Sarin, Mohammed Eslam, Jian-Gao Fan, Han-Chieh Lin, Jacob George, Masao Omata
Hepatology International.2022; 16(5): 1032. CrossRef The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population
Ji Yeon Seo, Eun Ju Cho, Min Joo Kim, Min‐Sun Kwak, Jong In Yang, Su Jin Chung, Jeong Yoon Yim, Ji Won Yoon, Goh Eun Chung
Journal of Cachexia, Sarcopenia and Muscle.2022; 13(6): 2953. CrossRef
MAFLD
: A quick fact check
Nahum Méndez‐Sánchez, Jian‐Gao Fan, Mohamed El‐Kassas, Marcos Girala
Liver International.2022; 42(12): 2903. CrossRef Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years
In-Ho Seo, Hye Sun Lee, Yong-Jae Lee
Cardiovascular Diabetology.2022;[Epub] CrossRef Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan
International Journal of Molecular Sciences.2022; 23(23): 14762. CrossRef
|